Pulmatrix IncNASDAQ:PULM
- LAST PRICE1.9600
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.9500/ 1
- Ask / Lots2.0400/ 2
- Open / Previous Close2.0294 / 1.9600
- Day Range
- 52 Week Range
- Volume9,491
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | PULM |
|---|---|---|
| 09:32 ET | 100 | 2.0294 |
| 09:34 ET | 100 | 2.03 |
| 09:52 ET | 200 | 2.04 |
| 09:57 ET | 500 | 2 |
| 10:14 ET | 1521 | 1.96 |
| 10:30 ET | 600 | 1.99 |
| 10:32 ET | 500 | 1.9518 |
| 10:35 ET | 862 | 1.94 |
| 10:39 ET | 2952 | 1.97 |
| 10:48 ET | 200 | 1.995 |
| 10:57 ET | 500 | 1.9501 |
| 11:11 ET | 400 | 1.96 |
Mar 28, 2024
Press Release: Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update, from 9:05AM ET on Thursday Mar 28, 2024 by Dow Jones
9:05AM ET on Thursday Mar 28, 2024 by Dow JonesPulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update, from 9:05AM ET on Thursday Mar 28, 2024 by Dow Jones
9:05AM ET on Thursday Mar 28, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Pulmatrix Inc | 7.2M | -0.5x | --- |
Fresh Tracks Therapeutics Inc | 5.4M | -0.7x | --- |
Tonix Pharmaceuticals Holding Corp | 13.3M | 0.0x | --- |
International Stem Cell Corp | 569.9K | -4.3x | --- |
Redhill Biopharma Ltd | 13.4M | 0.1x | --- |
Petros Pharmaceuticals Inc | 4.8M | -0.1x | --- |
Company Information
Pulmatrix, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat respiratory and other diseases with important unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders, such as acute migraine and serious lung diseases, such as chronic obstructive pulmonary disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). The Company’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes. The Company’s therapeutic candidates include PUR3100, PUR1800, and PUR1900. PUR3100 is the iSPERSE formulation of dihydroergotamine (DHE), for the treatment of acute migraine.
Contact Information
- Headquarters
- 36 Crosby Drive, Suite 100BEDFORD, MA, United States 01730
- Phone
- 781-357-2333
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Michael Higgins
- President, Chief Executive Officer, Director
- Teofilo Raad
- Interim Chief Financial Officer
- Peter Ludlum
- Vice President - Finance
- Michelle Siegert
- Independent Director
- Richard Batycky
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $7.2M |
|---|---|
Revenue (TTM) | $7.3M |
Shares Outstanding | 3.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.88 |
EPS | $-3.87 |
Book Value | $4.93 |
P/E Ratio | -0.5x |
Price/Sales (TTM) | 1.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -201.97% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
